VERAXA Biotech (NASDAQ: VRXA) has released new in vitro proof-of-concept data supporting its BiTAC-ADC platform, a technology designed to enhance the selectivity of antibody-drug conjugates (ADCs) in cancer treatment. The company reported that the BiTAC-ADC technology demonstrated selective activity against cancer cells while sparing healthy cells in early testing, and showed dose-dependent destruction of three-dimensional tumor cell spheroids in laboratory studies. These results mark a step forward for VERAXA's proprietary approach, which aims to activate therapeutic effects only within targeted tumor cells, potentially reducing off-target toxicity common with conventional ADCs.
The announcement comes as VERAXA prepares to engage with potential pharmaceutical and biotechnology partners during the BIO International Convention 2026 in San Diego. The company will present its BiTAC-ADC and BiTAC-TCE platforms for strategic collaborations, highlighting its diversified oncology pipeline that includes ADCs, T-cell engagers (TCEs), and other antibody-based formats.
VERAXA recently began trading on the NASDAQ Capital Market under the ticker symbol VRXA following the completion of its business combination with Voyager Acquisition Corp. The company's BiTAC technology is designed to improve the precision of antibody-based cancer therapies by ensuring that the therapeutic effect is localized to cancer cells, thereby minimizing damage to healthy tissues. While the platform remains in early development, the new data provide a foundation for further preclinical and clinical evaluation.
The company maintains a focused pipeline of next-generation cancer therapies, and the BiTAC-ADC platform represents a key component of its strategy to address limitations of current ADC technologies. By incorporating a tumor-specific activation mechanism, VERAXA aims to broaden the therapeutic window of ADCs, potentially enabling treatment of cancers that are currently difficult to target safely.
For more information about VERAXA Biotech and its platforms, visit the company's newsroom at https://ibn.fm/VRXA.
Forward-looking statements in this article involve risks and uncertainties, including those detailed in VERAXA's SEC filings. The company undertakes no duty to update this information unless required by law.
